Illumina Inc. (ILMN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Illumina ( ILMN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Illumina rose $2.63 (3.9%) to $70.62 on average volume. Throughout the day, 1,128,420 shares of Illumina exchanged hands as compared to its average daily volume of 1,353,000 shares. The stock ranged in a price between $68.56-$71.27 after having opened the day at $68.56 as compared to the previous trading day's close of $67.99. Other companies within the Drugs industry that increased today were: Epizyme ( EPZM), up 10.7%, Skystar Bio-Pharmaceutical Company ( SKBI), up 10.4%, Pacific Biosciences of California ( PACB), up 9.1% and Palatin Technologies ( PTN), up 8.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $8.4 billion and is part of the health care sector. The company has a P/E ratio of 90.5, above the S&P 500 P/E ratio of 17.7. Shares are up 22.1% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Illumina a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Amicus Therapeutics ( FOLD), down 20.4%, Oramed Pharmaceuticals ( ORMP), down 19.1%, Senesco Technologies ( SNTI), down 12.6% and Oxygen Biotherapeutics ( OXBT), down 11.2% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement